Filing Details

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

 

(Amendment No.     )*

 

CytoMed Therapeutics Limited

(Name of Issuer)

 

Ordinary Shares, no par value

(Title of Class of Securities)

 

Y1R80M106

(CUSIP Number)

 

Zeng Jieming

c/o 1 Commonwealth Lane #08-22

Singapore 149544

+65 6250 7738

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

April 14, 2023

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

(1)	Names of Reporting Persons   Zeng Jieming
(2)	Check the appropriate box if a member of a group (see instructions)   (a) ☐ (b) ☐
(3)	SEC use only
(4)	Source of Funds (See Instructions)   OO (1)
(5)	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
(6)	Citizenship or Place of Organization   People’s Republic of China

Number of	(7)	Sole voting power   589,239 (1)
shares beneficially owned by	(8)	Shared voting power
each reporting person	(9)	Sole dispositive power   589,239 (1)
with:	(10)	Shared dispositive power

(11)	Aggregate amount beneficially owned by each reporting person   589,239 (1)
(12)	Check if the aggregate amount in Row (11) excludes certain shares (see instructions)   ☐
(13)	Percent of class represented by amount in Row (11)   5.11% (1)
(14)	Type of reporting person (see instructions)   IN

 

(1) Consists of 589,239 ordinary shares held directly by Zeng Jieming. Zeng Jieming acquired the 589,239 ordinary shares as founder shares.

 

 

Item 1. Security and Issuer.

 

This Schedule 13D is filed (this “Schedule 13D”) by the Reporting Person (as identified above and defined below) with respect to the ordinary shares no par value (“Shares”) of CytoMed Therapeutics Limited, a Singapore company, with its principal executive offices located at 1 Commonwealth Lane #08-22, Singapore 149544.

 

Item 2. Identity and Background.

 

(a) This Schedule 13D is being filed by Zeng Jieming (the “Reporting Person”):

 

(b) The Reporting Person’s business address is c/o CytoMed Therapeutics Limited, 1 Commonwealth Lane #08-22, Singapore 149544.

 

(c) The Reporting Person is a director and the Chief Scientific and Medical Officer of the Issuer.

 

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f) The Reporting Person is a citizen of the People’s Republic of China.

 

Item 3. Source and Amount of Funds or Other Consideration.

 

The Reporting Person acquired all of the Shares beneficially owned by him as founder shares.

 

Item 4. Purpose of Transaction.

 

The Reporting Person acquired all of the Shares beneficially owned by him as founder shares. The Reporting Person holds the Shares for investment purposes. The Reporting Person is a member of the board of directors of the Issuer and serves as the Chief Scientific and Medical Officer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.

 

Item 5. Interest in Securities of the Issuer.

 

(a) Incorporated by reference to Items 11 and 13 of the Cover Page.

 

(b) Incorporated by reference to Items 7-10 of the Cover Page.

 

(c) None

 

(d) None

 

(e) N/A

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Lock-Up Agreement – Pursuant to the terms of a Lock-Up Agreement dated April 13, 2023 (the “Lock-Up Agreement”), a copy of the form of which is attached to this Schedule 13D as Exhibit 1 and incorporated herein by reference, the Reporting Person has agreed, subject to certain exceptions, not to offer, pledge, sell, or dispose of, directly or indirectly, any of the Issuer’s Ordinary Shares or securities convertible into or exchangeable or exercisable for any of the Issuer’s Ordinary Shares during the 12-month period following the date of the Underwriting Agreement, dated April 13, 2023, by and between the Issuer and The Benchmark Company, LLC, as representative of the several underwriters.

 

 

Item 7. Material to Be Filed as Exhibits.

 

Exhibit Number		Description
1		Form of Lock-Up Agreement.

 

 

SIGNATURES

 

After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date:	May 19, 2023	ZENG JIEMING
		/s/ZENG JIEMING